Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Neoplasms | 47 | 2024 | 4298 | 4.030 |
Why?
|
Testicular Neoplasms | 18 | 2024 | 806 | 3.620 |
Why?
|
Carcinoma, Renal Cell | 37 | 2024 | 3197 | 3.310 |
Why?
|
Fallopian Tube Neoplasms | 15 | 2022 | 329 | 2.140 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 10 | 2023 | 495 | 1.990 |
Why?
|
Immunohistochemistry | 53 | 2024 | 11138 | 1.800 |
Why?
|
Teratoma | 8 | 2024 | 405 | 1.760 |
Why?
|
Ovarian Neoplasms | 33 | 2024 | 4906 | 1.740 |
Why?
|
Adenoma, Oxyphilic | 6 | 2024 | 152 | 1.600 |
Why?
|
Cystadenocarcinoma, Serous | 19 | 2018 | 480 | 1.520 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 4 | 2023 | 78 | 1.520 |
Why?
|
Leiomyomatosis | 2 | 2022 | 69 | 1.500 |
Why?
|
Urinary Bladder Neoplasms | 14 | 2024 | 2254 | 1.490 |
Why?
|
Adenocarcinoma | 15 | 2024 | 6400 | 1.240 |
Why?
|
Paired Box Transcription Factors | 5 | 2013 | 206 | 1.190 |
Why?
|
Genital Neoplasms, Female | 5 | 2021 | 539 | 1.190 |
Why?
|
Uterine Neoplasms | 6 | 2023 | 1422 | 1.150 |
Why?
|
Prostatic Neoplasms | 26 | 2024 | 11206 | 1.140 |
Why?
|
Paget Disease, Extramammary | 2 | 2023 | 52 | 1.120 |
Why?
|
Carcinoma, Transitional Cell | 7 | 2024 | 798 | 1.000 |
Why?
|
Kidney Medulla | 3 | 2021 | 169 | 1.000 |
Why?
|
GATA3 Transcription Factor | 3 | 2024 | 164 | 1.000 |
Why?
|
SOXD Transcription Factors | 2 | 2022 | 44 | 0.980 |
Why?
|
Endodermal Sinus Tumor | 2 | 2022 | 53 | 0.980 |
Why?
|
SOXF Transcription Factors | 1 | 2024 | 31 | 0.950 |
Why?
|
Carcinoma | 8 | 2022 | 2341 | 0.940 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 3 | 2022 | 196 | 0.920 |
Why?
|
Diagnosis, Differential | 28 | 2024 | 13026 | 0.890 |
Why?
|
Metaplasia | 3 | 2021 | 326 | 0.880 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 2 | 2021 | 43 | 0.860 |
Why?
|
Antigens, Neoplasm | 3 | 2020 | 2003 | 0.840 |
Why?
|
Adenomatoid Tumor | 1 | 2022 | 12 | 0.810 |
Why?
|
Sarcoma | 6 | 2023 | 1806 | 0.800 |
Why?
|
Epithelioid Cells | 1 | 2022 | 60 | 0.770 |
Why?
|
Smooth Muscle Tumor | 2 | 2020 | 65 | 0.770 |
Why?
|
Peritoneal Neoplasms | 4 | 2022 | 715 | 0.770 |
Why?
|
Catenins | 1 | 2021 | 44 | 0.760 |
Why?
|
Seminal Vesicles | 1 | 2021 | 103 | 0.750 |
Why?
|
Endometrial Neoplasms | 7 | 2024 | 1382 | 0.720 |
Why?
|
Melanoma-Specific Antigens | 1 | 2020 | 74 | 0.720 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2021 | 526 | 0.720 |
Why?
|
Chromosomes, Human, X | 4 | 2015 | 321 | 0.720 |
Why?
|
Carcinoma, Papillary | 4 | 2024 | 792 | 0.710 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2021 | 555 | 0.710 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 5 | 2022 | 325 | 0.680 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2024 | 2040 | 0.660 |
Why?
|
In Situ Hybridization, Fluorescence | 8 | 2024 | 2525 | 0.660 |
Why?
|
Uterine Cervical Dysplasia | 3 | 2013 | 387 | 0.650 |
Why?
|
Urothelium | 1 | 2021 | 275 | 0.650 |
Why?
|
Stathmin | 3 | 2015 | 70 | 0.630 |
Why?
|
Urethra | 1 | 2020 | 406 | 0.610 |
Why?
|
Ganglioneuroma | 1 | 2018 | 53 | 0.600 |
Why?
|
Plasma Cells | 1 | 2021 | 598 | 0.590 |
Why?
|
Translocation, Genetic | 6 | 2015 | 1395 | 0.580 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 3 | 2024 | 118 | 0.570 |
Why?
|
Wolffian Ducts | 2 | 2018 | 27 | 0.550 |
Why?
|
Carcinoma in Situ | 6 | 2022 | 791 | 0.540 |
Why?
|
Precancerous Conditions | 5 | 2021 | 988 | 0.530 |
Why?
|
Fumarate Hydratase | 3 | 2022 | 55 | 0.530 |
Why?
|
Angiomyolipoma | 1 | 2017 | 188 | 0.520 |
Why?
|
Terminology as Topic | 4 | 2021 | 1539 | 0.520 |
Why?
|
Oncogenes | 4 | 2023 | 1235 | 0.510 |
Why?
|
Male Urogenital Diseases | 1 | 2015 | 48 | 0.510 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2015 | 27 | 0.500 |
Why?
|
Female Urogenital Diseases | 1 | 2015 | 57 | 0.500 |
Why?
|
Humans | 171 | 2024 | 768451 | 0.490 |
Why?
|
Predictive Value of Tests | 18 | 2022 | 15460 | 0.490 |
Why?
|
Urinary Bladder | 2 | 2020 | 1160 | 0.480 |
Why?
|
Radiotherapy | 1 | 2021 | 1510 | 0.460 |
Why?
|
Adenoma | 3 | 2021 | 2163 | 0.460 |
Why?
|
Prostate | 9 | 2022 | 1781 | 0.450 |
Why?
|
Repressor Proteins | 2 | 2023 | 2987 | 0.450 |
Why?
|
Carcinoma, Endometrioid | 3 | 2014 | 276 | 0.450 |
Why?
|
Neoplasm Proteins | 4 | 2021 | 3611 | 0.440 |
Why?
|
Trophoblasts | 1 | 2015 | 224 | 0.430 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 712 | 0.410 |
Why?
|
Pelvic Neoplasms | 4 | 2023 | 250 | 0.410 |
Why?
|
Sertoli Cell Tumor | 2 | 2023 | 36 | 0.400 |
Why?
|
Female | 96 | 2024 | 396943 | 0.400 |
Why?
|
Male | 86 | 2024 | 364781 | 0.390 |
Why?
|
Prostatectomy | 9 | 2024 | 1840 | 0.390 |
Why?
|
Neoplastic Syndromes, Hereditary | 3 | 2024 | 249 | 0.390 |
Why?
|
Neoplasm Invasiveness | 8 | 2024 | 3637 | 0.390 |
Why?
|
Adipose Tissue | 1 | 2024 | 3335 | 0.390 |
Why?
|
Seminoma | 2 | 2023 | 136 | 0.380 |
Why?
|
Mesonephroma | 2 | 2024 | 21 | 0.370 |
Why?
|
Carcinoma, Medullary | 2 | 2017 | 116 | 0.360 |
Why?
|
Lymphoma, T-Cell | 1 | 2012 | 304 | 0.340 |
Why?
|
Fallopian Tubes | 5 | 2023 | 179 | 0.340 |
Why?
|
Aged | 60 | 2024 | 171520 | 0.330 |
Why?
|
Testis | 2 | 2024 | 783 | 0.320 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2009 | 410 | 0.320 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2022 | 342 | 0.320 |
Why?
|
Melanoma | 3 | 2023 | 5740 | 0.320 |
Why?
|
Mutation | 23 | 2024 | 30243 | 0.310 |
Why?
|
Vulvar Neoplasms | 2 | 2008 | 267 | 0.310 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2022 | 8635 | 0.310 |
Why?
|
Pathology | 2 | 2021 | 270 | 0.290 |
Why?
|
Middle Aged | 60 | 2024 | 223418 | 0.290 |
Why?
|
Tumor Suppressor Protein p53 | 12 | 2022 | 2964 | 0.280 |
Why?
|
Biopsy | 12 | 2023 | 6816 | 0.280 |
Why?
|
Pyrroles | 2 | 2010 | 1127 | 0.270 |
Why?
|
Adult | 45 | 2024 | 223542 | 0.260 |
Why?
|
Skin Neoplasms | 3 | 2022 | 5891 | 0.260 |
Why?
|
Neuroendocrine Tumors | 2 | 2023 | 649 | 0.260 |
Why?
|
Lymphoma, B-Cell | 1 | 2012 | 945 | 0.260 |
Why?
|
Kidney Tubules, Collecting | 2 | 2018 | 163 | 0.250 |
Why?
|
Hysterectomy | 2 | 2010 | 863 | 0.250 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2016 | 489 | 0.250 |
Why?
|
Antineoplastic Agents | 7 | 2024 | 13708 | 0.250 |
Why?
|
Pleural Neoplasms | 1 | 2010 | 612 | 0.240 |
Why?
|
Cell Proliferation | 11 | 2022 | 10494 | 0.240 |
Why?
|
Granulosa Cell Tumor | 2 | 2024 | 78 | 0.240 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4083 | 0.240 |
Why?
|
Indoles | 2 | 2010 | 1834 | 0.240 |
Why?
|
Prostate-Specific Antigen | 7 | 2022 | 2483 | 0.230 |
Why?
|
Blood Vessels | 1 | 2010 | 1112 | 0.230 |
Why?
|
Lymph Nodes | 2 | 2015 | 3472 | 0.230 |
Why?
|
Aged, 80 and over | 22 | 2024 | 59680 | 0.230 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7451 | 0.220 |
Why?
|
Mesothelioma | 1 | 2010 | 811 | 0.220 |
Why?
|
Soft Tissue Neoplasms | 2 | 2023 | 1166 | 0.220 |
Why?
|
Blotting, Western | 4 | 2015 | 5042 | 0.210 |
Why?
|
beta Catenin | 2 | 2021 | 1048 | 0.210 |
Why?
|
Neoplasms, Second Primary | 2 | 2008 | 1062 | 0.210 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1766 | 0.210 |
Why?
|
Chromosomes, Human, Pair 3 | 2 | 2008 | 323 | 0.210 |
Why?
|
Malacoplakia | 1 | 2022 | 15 | 0.210 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2023 | 34 | 0.210 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 2022 | 28 | 0.200 |
Why?
|
DNA Mutational Analysis | 6 | 2018 | 4120 | 0.200 |
Why?
|
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2022 | 24 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2014 | 2847 | 0.200 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2022 | 467 | 0.190 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2022 | 169 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9425 | 0.190 |
Why?
|
Spermatogonia | 1 | 2021 | 30 | 0.190 |
Why?
|
Granular Cell Tumor | 1 | 2021 | 48 | 0.190 |
Why?
|
Genes, BRCA2 | 4 | 2013 | 592 | 0.190 |
Why?
|
Leydig Cell Tumor | 1 | 2021 | 29 | 0.190 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2002 | 370 | 0.190 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2010 | 595 | 0.190 |
Why?
|
Artifacts | 1 | 2010 | 1927 | 0.190 |
Why?
|
Vulvar Diseases | 1 | 2021 | 64 | 0.180 |
Why?
|
gp100 Melanoma Antigen | 1 | 2020 | 38 | 0.180 |
Why?
|
Genes, BRCA1 | 4 | 2013 | 755 | 0.180 |
Why?
|
MART-1 Antigen | 1 | 2020 | 63 | 0.180 |
Why?
|
Chorionic Gonadotropin | 1 | 2023 | 458 | 0.180 |
Why?
|
Laryngeal Neoplasms | 1 | 2004 | 515 | 0.180 |
Why?
|
Birt-Hogg-Dube Syndrome | 1 | 2020 | 40 | 0.170 |
Why?
|
Uterine Cervical Diseases | 1 | 2020 | 75 | 0.170 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2020 | 67 | 0.170 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 258 | 0.170 |
Why?
|
Carcinoma, Ductal | 1 | 2020 | 97 | 0.170 |
Why?
|
Receptors, Somatostatin | 1 | 2020 | 138 | 0.170 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2024 | 109 | 0.170 |
Why?
|
Cell Differentiation | 5 | 2021 | 11674 | 0.170 |
Why?
|
Vaginal Diseases | 1 | 2020 | 103 | 0.160 |
Why?
|
Colorectal Neoplasms | 4 | 2024 | 6978 | 0.160 |
Why?
|
Cell Nucleus | 3 | 2021 | 2889 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2021 | 3665 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
Choristoma | 1 | 2020 | 205 | 0.160 |
Why?
|
Kallikreins | 1 | 2020 | 221 | 0.160 |
Why?
|
Succinate Dehydrogenase | 2 | 2021 | 148 | 0.160 |
Why?
|
Tissue Array Analysis | 4 | 2016 | 551 | 0.150 |
Why?
|
Chromosome Aberrations | 3 | 2024 | 1781 | 0.150 |
Why?
|
Smad4 Protein | 1 | 2019 | 193 | 0.150 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11249 | 0.150 |
Why?
|
Urology | 2 | 2020 | 411 | 0.150 |
Why?
|
Reproducibility of Results | 8 | 2023 | 20231 | 0.150 |
Why?
|
Gadolinium DTPA | 3 | 2017 | 823 | 0.150 |
Why?
|
Retrospective Studies | 19 | 2024 | 81834 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2020 | 218 | 0.140 |
Why?
|
Thyroid Gland | 1 | 2004 | 1172 | 0.140 |
Why?
|
Tumor Suppressor Proteins | 3 | 2022 | 2819 | 0.140 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 618 | 0.140 |
Why?
|
Gene Expression Profiling | 8 | 2021 | 9507 | 0.140 |
Why?
|
5-Methylcytosine | 1 | 2017 | 147 | 0.140 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2017 | 35 | 0.140 |
Why?
|
Gene Amplification | 4 | 2014 | 1091 | 0.130 |
Why?
|
Cadherins | 1 | 2021 | 906 | 0.130 |
Why?
|
Ki-67 Antigen | 3 | 2015 | 631 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2022 | 1614 | 0.130 |
Why?
|
Sarcoidosis | 1 | 2022 | 539 | 0.130 |
Why?
|
Saposins | 1 | 2016 | 22 | 0.130 |
Why?
|
Northern Ireland | 1 | 2015 | 37 | 0.130 |
Why?
|
Gene Rearrangement | 1 | 2021 | 1139 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 12 | 2024 | 36840 | 0.130 |
Why?
|
Neoadjuvant Therapy | 3 | 2019 | 2896 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2224 | 0.120 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2019 | 959 | 0.120 |
Why?
|
Specialization | 1 | 2020 | 782 | 0.120 |
Why?
|
Histone Code | 1 | 2016 | 160 | 0.120 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 93 | 0.120 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2021 | 614 | 0.120 |
Why?
|
Germ Cells | 1 | 2018 | 641 | 0.120 |
Why?
|
Karyotyping | 2 | 2009 | 1173 | 0.120 |
Why?
|
Disease Progression | 6 | 2020 | 13655 | 0.120 |
Why?
|
Urogenital Neoplasms | 1 | 2015 | 133 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11843 | 0.120 |
Why?
|
S100 Proteins | 1 | 2015 | 217 | 0.120 |
Why?
|
Thrombospondin 1 | 1 | 2016 | 259 | 0.120 |
Why?
|
Nephrectomy | 5 | 2024 | 949 | 0.110 |
Why?
|
Biological Products | 1 | 2023 | 937 | 0.110 |
Why?
|
Keratin-7 | 2 | 2017 | 55 | 0.110 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2067 | 0.110 |
Why?
|
Papillomavirus Infections | 2 | 2020 | 1638 | 0.110 |
Why?
|
Ubiquitination | 1 | 2018 | 1010 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2023 | 1418 | 0.110 |
Why?
|
Peptides, Cyclic | 1 | 2016 | 393 | 0.110 |
Why?
|
Health Resources | 1 | 2020 | 950 | 0.110 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2015 | 2072 | 0.110 |
Why?
|
Ovary | 1 | 2018 | 960 | 0.110 |
Why?
|
Leuprolide | 1 | 2015 | 313 | 0.110 |
Why?
|
Meningioma | 1 | 2022 | 1222 | 0.110 |
Why?
|
Octamer Transcription Factor-3 | 2 | 2016 | 221 | 0.110 |
Why?
|
Cyclin E | 1 | 2013 | 156 | 0.110 |
Why?
|
Observer Variation | 5 | 2021 | 2622 | 0.110 |
Why?
|
Meningeal Neoplasms | 1 | 2022 | 1251 | 0.110 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2015 | 640 | 0.110 |
Why?
|
Protective Agents | 1 | 2014 | 151 | 0.110 |
Why?
|
Prognosis | 12 | 2019 | 30028 | 0.110 |
Why?
|
Antibodies, Monoclonal | 3 | 2020 | 9263 | 0.110 |
Why?
|
Calcinosis | 1 | 2022 | 1485 | 0.110 |
Why?
|
Inhibitor of Differentiation Proteins | 1 | 2012 | 17 | 0.100 |
Why?
|
Young Adult | 13 | 2022 | 60045 | 0.100 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 163 | 0.100 |
Why?
|
Cell Lineage | 2 | 2018 | 2575 | 0.100 |
Why?
|
Isoenzymes | 1 | 2017 | 1685 | 0.100 |
Why?
|
Protein Kinase C | 1 | 2017 | 1207 | 0.100 |
Why?
|
Racemases and Epimerases | 2 | 2021 | 114 | 0.100 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 14728 | 0.100 |
Why?
|
Antigens, CD | 2 | 2021 | 4029 | 0.100 |
Why?
|
Immunoenzyme Techniques | 3 | 2010 | 1706 | 0.100 |
Why?
|
Gene Order | 1 | 2011 | 169 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 631 | 0.090 |
Why?
|
Intestines | 1 | 2020 | 1912 | 0.090 |
Why?
|
Lymphatic Metastasis | 2 | 2017 | 2930 | 0.090 |
Why?
|
Cell Line, Tumor | 7 | 2016 | 17149 | 0.090 |
Why?
|
Pelvis | 1 | 2015 | 737 | 0.090 |
Why?
|
Nuclear Proteins | 2 | 2009 | 5808 | 0.090 |
Why?
|
Risk Assessment | 7 | 2021 | 24311 | 0.090 |
Why?
|
Carcinoma, Islet Cell | 1 | 2010 | 21 | 0.090 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1357 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2022 | 4642 | 0.090 |
Why?
|
Biopsy, Needle | 3 | 2021 | 1629 | 0.090 |
Why?
|
Adenoma, Islet Cell | 1 | 2010 | 72 | 0.090 |
Why?
|
Transcription Factors | 4 | 2023 | 12174 | 0.090 |
Why?
|
Epithelial Cells | 2 | 2020 | 3697 | 0.090 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2010 | 66 | 0.090 |
Why?
|
Lung Diseases | 1 | 2020 | 1926 | 0.090 |
Why?
|
Receptor, Notch1 | 1 | 2013 | 521 | 0.090 |
Why?
|
Elafin | 1 | 2010 | 31 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2020 | 1676 | 0.090 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1484 | 0.090 |
Why?
|
Appendectomy | 1 | 2013 | 442 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2016 | 5342 | 0.090 |
Why?
|
Phenotype | 8 | 2022 | 16712 | 0.090 |
Why?
|
Tumor Microenvironment | 3 | 2021 | 3939 | 0.080 |
Why?
|
Oncogene Proteins | 1 | 2013 | 718 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2014 | 2884 | 0.080 |
Why?
|
Cystectomy | 1 | 2014 | 644 | 0.080 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1104 | 0.080 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 1368 | 0.080 |
Why?
|
Neoplasm Metastasis | 4 | 2016 | 4931 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1905 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 906 | 0.080 |
Why?
|
Societies, Medical | 1 | 2021 | 3955 | 0.080 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2010 | 239 | 0.080 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2012 | 335 | 0.080 |
Why?
|
Keratin-19 | 1 | 2008 | 33 | 0.080 |
Why?
|
HLA-D Antigens | 1 | 2008 | 130 | 0.080 |
Why?
|
Nucleic Acid Hybridization | 1 | 2010 | 1305 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2012 | 568 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2019 | 6537 | 0.080 |
Why?
|
Carcinoid Tumor | 1 | 2010 | 226 | 0.080 |
Why?
|
Loss of Heterozygosity | 2 | 2023 | 663 | 0.080 |
Why?
|
Ascites | 1 | 2010 | 339 | 0.080 |
Why?
|
Histones | 1 | 2018 | 2595 | 0.080 |
Why?
|
Laparoscopy | 2 | 2010 | 2056 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 496 | 0.070 |
Why?
|
SEER Program | 1 | 2013 | 1476 | 0.070 |
Why?
|
Cytoskeletal Proteins | 2 | 2013 | 1337 | 0.070 |
Why?
|
Immune Tolerance | 1 | 2017 | 2326 | 0.070 |
Why?
|
Health Care Surveys | 3 | 2021 | 2437 | 0.070 |
Why?
|
Vulva | 1 | 2008 | 84 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2017 | 2823 | 0.070 |
Why?
|
Chromosomes, Human, Pair 12 | 2 | 2023 | 431 | 0.070 |
Why?
|
Treatment Outcome | 12 | 2020 | 65409 | 0.070 |
Why?
|
Contrast Media | 5 | 2024 | 5336 | 0.070 |
Why?
|
Genes, p53 | 4 | 2013 | 716 | 0.070 |
Why?
|
SOXB1 Transcription Factors | 1 | 2009 | 286 | 0.070 |
Why?
|
Genomics | 5 | 2023 | 5909 | 0.070 |
Why?
|
Child | 10 | 2022 | 80863 | 0.070 |
Why?
|
Sex Factors | 1 | 2021 | 10647 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 6 | 2024 | 20762 | 0.070 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2017 | 2910 | 0.070 |
Why?
|
Boston | 3 | 2015 | 9361 | 0.070 |
Why?
|
Epigenesis, Genetic | 2 | 2017 | 3826 | 0.070 |
Why?
|
Pancreatic Neoplasms | 2 | 2018 | 5442 | 0.070 |
Why?
|
Molecular Targeted Therapy | 2 | 2016 | 2834 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2017 | 1797 | 0.070 |
Why?
|
Chromatin | 1 | 2018 | 2969 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 7 | 2021 | 18048 | 0.070 |
Why?
|
Vaginal Neoplasms | 1 | 2007 | 105 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 937 | 0.070 |
Why?
|
Hernia, Ventral | 1 | 2010 | 220 | 0.070 |
Why?
|
Cervix Uteri | 1 | 2010 | 577 | 0.070 |
Why?
|
Gene Frequency | 1 | 2013 | 3615 | 0.070 |
Why?
|
Databases, Factual | 1 | 2022 | 8081 | 0.070 |
Why?
|
RNA, Messenger | 3 | 2016 | 12813 | 0.060 |
Why?
|
Time Factors | 6 | 2020 | 40271 | 0.060 |
Why?
|
Nevus, Pigmented | 1 | 2008 | 225 | 0.060 |
Why?
|
Microtubules | 1 | 2011 | 1074 | 0.060 |
Why?
|
Risk Factors | 8 | 2021 | 74915 | 0.060 |
Why?
|
Survival Analysis | 4 | 2021 | 10125 | 0.060 |
Why?
|
Biopsy, Fine-Needle | 2 | 2024 | 1131 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9182 | 0.060 |
Why?
|
Organ Size | 1 | 2010 | 2268 | 0.060 |
Why?
|
Corpus Luteum | 1 | 2004 | 81 | 0.060 |
Why?
|
Receptors, Progesterone | 1 | 2009 | 1145 | 0.060 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2004 | 81 | 0.060 |
Why?
|
Muscle Proteins | 1 | 2009 | 1165 | 0.060 |
Why?
|
Genotype | 3 | 2013 | 13047 | 0.060 |
Why?
|
Androgens | 2 | 2023 | 1285 | 0.060 |
Why?
|
Genomic Instability | 1 | 2008 | 714 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2016 | 3520 | 0.060 |
Why?
|
Homeodomain Proteins | 2 | 2012 | 2430 | 0.060 |
Why?
|
Chromosome Duplication | 1 | 2023 | 76 | 0.060 |
Why?
|
Apoptosis | 3 | 2018 | 9526 | 0.060 |
Why?
|
Genome, Human | 1 | 2016 | 4453 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2742 | 0.050 |
Why?
|
Signal Transduction | 7 | 2021 | 23638 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2239 | 0.050 |
Why?
|
Epithelium | 3 | 2013 | 1610 | 0.050 |
Why?
|
RNA, Small Interfering | 1 | 2012 | 3437 | 0.050 |
Why?
|
Robotics | 1 | 2010 | 826 | 0.050 |
Why?
|
Calcitonin | 1 | 2004 | 329 | 0.050 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2024 | 195 | 0.050 |
Why?
|
Mitochondria | 2 | 2016 | 3672 | 0.050 |
Why?
|
Methotrexate | 2 | 2023 | 1722 | 0.050 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2015 | 3408 | 0.050 |
Why?
|
Medical Errors | 1 | 2010 | 1263 | 0.050 |
Why?
|
Orchiectomy | 1 | 2024 | 466 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2022 | 200 | 0.050 |
Why?
|
NF-kappa B | 1 | 2010 | 2491 | 0.050 |
Why?
|
Receptors, Estrogen | 1 | 2009 | 2243 | 0.050 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 272 | 0.050 |
Why?
|
Nucleotides | 1 | 2023 | 455 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2526 | 0.050 |
Why?
|
Specimen Handling | 2 | 2020 | 709 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 333 | 0.050 |
Why?
|
Genetic Heterogeneity | 1 | 2024 | 738 | 0.040 |
Why?
|
Disease-Free Survival | 3 | 2019 | 6856 | 0.040 |
Why?
|
Nanoparticles | 1 | 2012 | 1986 | 0.040 |
Why?
|
Chromatin Immunoprecipitation | 2 | 2016 | 856 | 0.040 |
Why?
|
BCG Vaccine | 1 | 2023 | 383 | 0.040 |
Why?
|
Neprilysin | 1 | 2003 | 487 | 0.040 |
Why?
|
Keratins | 1 | 2021 | 502 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2010 | 2179 | 0.040 |
Why?
|
Granuloma | 1 | 2022 | 331 | 0.040 |
Why?
|
Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2018 | 2039 | 0.040 |
Why?
|
Telomerase | 1 | 2024 | 751 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 356 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 433 | 0.040 |
Why?
|
DNA Copy Number Variations | 2 | 2018 | 2046 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 2586 | 0.040 |
Why?
|
Alleles | 3 | 2017 | 6890 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2018 | 6135 | 0.040 |
Why?
|
Aneuploidy | 1 | 2022 | 572 | 0.040 |
Why?
|
Adolescent | 8 | 2022 | 89168 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2015 | 39430 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9505 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1154 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2017 | 3619 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 3713 | 0.040 |
Why?
|
Cohort Studies | 4 | 2015 | 41797 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 560 | 0.040 |
Why?
|
Omentum | 1 | 2019 | 168 | 0.040 |
Why?
|
Tumor Burden | 2 | 2015 | 1909 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2022 | 726 | 0.040 |
Why?
|
Online Systems | 1 | 2019 | 182 | 0.040 |
Why?
|
Mitosis | 1 | 2023 | 1191 | 0.040 |
Why?
|
Mice | 8 | 2017 | 82045 | 0.040 |
Why?
|
Necrosis | 1 | 2021 | 1621 | 0.040 |
Why?
|
Mullerian Ducts | 1 | 2018 | 203 | 0.030 |
Why?
|
Epigenomics | 1 | 2023 | 956 | 0.030 |
Why?
|
Mitotic Index | 1 | 2017 | 164 | 0.030 |
Why?
|
Muscles | 1 | 2021 | 1582 | 0.030 |
Why?
|
Cell Survival | 2 | 2017 | 5801 | 0.030 |
Why?
|
Fibronectins | 1 | 2020 | 725 | 0.030 |
Why?
|
Proportional Hazards Models | 4 | 2014 | 12561 | 0.030 |
Why?
|
Transsexualism | 1 | 2020 | 210 | 0.030 |
Why?
|
Cyclization | 1 | 2016 | 59 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 2 | 2013 | 1119 | 0.030 |
Why?
|
Animals | 10 | 2017 | 169418 | 0.030 |
Why?
|
Early Detection of Cancer | 1 | 2010 | 3230 | 0.030 |
Why?
|
DNA Methylation | 2 | 2022 | 4421 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2013 | 5367 | 0.030 |
Why?
|
Doxorubicin | 2 | 2014 | 2229 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1625 | 0.030 |
Why?
|
Dioxygenases | 1 | 2017 | 351 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.030 |
Why?
|
Microfilament Proteins | 2 | 2013 | 1136 | 0.030 |
Why?
|
Whole Body Imaging | 1 | 2017 | 285 | 0.030 |
Why?
|
Paraffin Embedding | 1 | 2016 | 306 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2016 | 245 | 0.030 |
Why?
|
Palliative Care | 1 | 2010 | 3644 | 0.030 |
Why?
|
Neoplasms | 2 | 2016 | 22386 | 0.030 |
Why?
|
Morphogenesis | 1 | 2018 | 747 | 0.030 |
Why?
|
World Health Organization | 1 | 2021 | 1328 | 0.030 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 756 | 0.030 |
Why?
|
Pathology, Clinical | 1 | 2018 | 377 | 0.030 |
Why?
|
Formaldehyde | 1 | 2016 | 361 | 0.030 |
Why?
|
Endometriosis | 1 | 2003 | 873 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2002 | 4622 | 0.030 |
Why?
|
Filgrastim | 1 | 2014 | 132 | 0.030 |
Why?
|
Australia | 1 | 2018 | 1264 | 0.030 |
Why?
|
Brazil | 1 | 2018 | 1247 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2014 | 3550 | 0.030 |
Why?
|
Data Mining | 1 | 2018 | 561 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5308 | 0.030 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7599 | 0.030 |
Why?
|
Pregnancy | 1 | 2015 | 30179 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 16029 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2014 | 3794 | 0.030 |
Why?
|
Morpholines | 1 | 2016 | 583 | 0.030 |
Why?
|
Prospective Studies | 4 | 2023 | 54914 | 0.030 |
Why?
|
Vinblastine | 1 | 2014 | 488 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12096 | 0.030 |
Why?
|
DNA-Binding Proteins | 3 | 2017 | 9623 | 0.030 |
Why?
|
Canada | 1 | 2018 | 2143 | 0.030 |
Why?
|
Cell Cycle Proteins | 2 | 2017 | 3463 | 0.020 |
Why?
|
Aminopyridines | 1 | 2016 | 578 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4586 | 0.020 |
Why?
|
GTP Phosphohydrolases | 1 | 2015 | 525 | 0.020 |
Why?
|
Subcutaneous Tissue | 1 | 2012 | 132 | 0.020 |
Why?
|
Phosphorylation | 2 | 2013 | 8332 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1750 | 0.020 |
Why?
|
Endonucleases | 1 | 2014 | 371 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 381 | 0.020 |
Why?
|
Integrases | 1 | 2013 | 520 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2016 | 22365 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3207 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3439 | 0.020 |
Why?
|
Child, Preschool | 3 | 2022 | 42623 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1608 | 0.020 |
Why?
|
Cell Death | 1 | 2016 | 1684 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2011 | 297 | 0.020 |
Why?
|
Open Reading Frames | 1 | 2014 | 812 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 506 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 319 | 0.020 |
Why?
|
Health Surveys | 1 | 2020 | 4056 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6091 | 0.020 |
Why?
|
PAX2 Transcription Factor | 1 | 2010 | 86 | 0.020 |
Why?
|
Cell Polarity | 1 | 2013 | 639 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2017 | 0.020 |
Why?
|
Desmin | 1 | 2009 | 99 | 0.020 |
Why?
|
Referral and Consultation | 2 | 2013 | 3629 | 0.020 |
Why?
|
Genes, p16 | 1 | 2010 | 160 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2013 | 660 | 0.020 |
Why?
|
Amino Acids | 1 | 2016 | 1714 | 0.020 |
Why?
|
Gene Dosage | 1 | 2014 | 1221 | 0.020 |
Why?
|
Permeability | 1 | 2011 | 725 | 0.020 |
Why?
|
Testosterone | 1 | 2020 | 2493 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7605 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2010 | 699 | 0.020 |
Why?
|
Microdissection | 1 | 2009 | 151 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2846 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 1794 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2018 | 3234 | 0.020 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2008 | 60 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1195 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2017 | 2450 | 0.020 |
Why?
|
Blotting, Northern | 1 | 2010 | 1553 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1897 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2010 | 681 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 6008 | 0.020 |
Why?
|
Cisplatin | 1 | 2014 | 1661 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2008 | 270 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2010 | 890 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2015 | 7895 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2017 | 18388 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2012 | 1246 | 0.020 |
Why?
|
Mice, Nude | 1 | 2014 | 3635 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2018 | 3612 | 0.020 |
Why?
|
DNA Primers | 1 | 2011 | 2826 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2531 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2008 | 347 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3546 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6353 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2007 | 348 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 695 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4861 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2014 | 22293 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3624 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5797 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2009 | 727 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4362 | 0.020 |
Why?
|
Random Allocation | 1 | 2010 | 2399 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8559 | 0.020 |
Why?
|
Remission Induction | 1 | 2011 | 2408 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 952 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2008 | 752 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2010 | 13589 | 0.020 |
Why?
|
Ultrasonography | 2 | 2012 | 5995 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5709 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4534 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2012 | 3103 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8510 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5223 | 0.020 |
Why?
|
Cytoplasm | 1 | 2009 | 1503 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4728 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4780 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1409 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2014 | 2594 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2017 | 9558 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2014 | 6527 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2008 | 2477 | 0.010 |
Why?
|
Image Enhancement | 1 | 2015 | 2894 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2011 | 2204 | 0.010 |
Why?
|
Incidental Findings | 1 | 2009 | 699 | 0.010 |
Why?
|
Adenosine Triphosphatases | 1 | 2008 | 842 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2012 | 1738 | 0.010 |
Why?
|
Islets of Langerhans | 1 | 2010 | 1349 | 0.010 |
Why?
|
Quinazolines | 1 | 2010 | 1376 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2010 | 1277 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6995 | 0.010 |
Why?
|
Algorithms | 2 | 2015 | 14158 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2015 | 2489 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2010 | 21156 | 0.010 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 863 | 0.010 |
Why?
|
Exons | 1 | 2008 | 2392 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1557 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10865 | 0.010 |
Why?
|
Embryonic Stem Cells | 1 | 2009 | 1249 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7449 | 0.010 |
Why?
|
Myometrium | 1 | 2003 | 174 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2062 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2012 | 2643 | 0.010 |
Why?
|
Computer Simulation | 1 | 2015 | 6278 | 0.010 |
Why?
|
RNA Interference | 1 | 2010 | 2832 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2007 | 1615 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6657 | 0.010 |
Why?
|
Gene Deletion | 1 | 2008 | 2674 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4266 | 0.010 |
Why?
|
Endometrium | 1 | 2003 | 407 | 0.010 |
Why?
|
Odds Ratio | 1 | 2012 | 9687 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2011 | 5152 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36497 | 0.010 |
Why?
|
Quality of Life | 1 | 2019 | 13497 | 0.010 |
Why?
|
Survival Rate | 1 | 2012 | 12875 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10601 | 0.010 |
Why?
|
Logistic Models | 1 | 2012 | 13324 | 0.010 |
Why?
|
Trans-Activators | 1 | 2007 | 2858 | 0.010 |
Why?
|
Stromal Cells | 1 | 2003 | 1335 | 0.010 |
Why?
|
United States | 2 | 2018 | 73121 | 0.010 |
Why?
|
Kidney | 1 | 2012 | 7064 | 0.010 |
Why?
|
MicroRNAs | 1 | 2012 | 3805 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2011 | 3623 | 0.010 |
Why?
|
Postmenopause | 1 | 2004 | 2519 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18478 | 0.010 |
Why?
|
Decision Making | 1 | 2008 | 3961 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4362 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5192 | 0.010 |
Why?
|
Prevalence | 1 | 2010 | 15880 | 0.010 |
Why?
|